Warning Letter: New Sponsor, Same Violative Promotional Practices For Insomnia Drug Doral

 
• By Michael Cipriano
  
WarningSign_1200x675
The FDA sent a warning letter to Galt for allegedly misbranding its insomnia drog Doral.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Marketing & Advertising

More from Compliance